Garrison Financial Has Lowered Abbvie (ABBV) Position By $646,720; Belmont Bancorp Has 1.15 Sentiment

June 23, 2018 - By Adrian Mccoy

BSB Bancorp, Inc. (NASDAQ:BLMT) Logo

Belmont Bancorp (BLMT) investors sentiment decreased to 1.15 in 2018 Q1. It’s down -0.22, from 1.37 in 2017Q4. The ratio fall, as 23 hedge funds opened new and increased holdings, while 20 reduced and sold their stock positions in Belmont Bancorp. The hedge funds in our database now hold: 4.68 million shares, up from 4.63 million shares in 2017Q4. Also, the number of hedge funds holding Belmont Bancorp in top ten holdings increased from 0 to 1 for an increase of 1. Sold All: 3 Reduced: 17 Increased: 16 New Position: 7.

Garrison Financial Corp decreased Abbvie Inc. (ABBV) stake by 10.42% reported in 2018Q1 SEC filing. Garrison Financial Corp sold 6,880 shares as Abbvie Inc. (ABBV)’s stock declined 16.83%. The Garrison Financial Corp holds 59,120 shares with $5.60 million value, down from 66,000 last quarter. Abbvie Inc. now has $141.55B valuation. The stock decreased 2.16% or $2.06 during the last trading session, reaching $93.49. About 9.75 million shares traded or 9.68% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 23, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 26/04/2018 – AbbVie unveils $7.5bn share buyback; 26/03/2018 – ABBVIE INC ABBV.N : CITIGROUP RAISES TARGET PRICE TO $96 FROM $93; 25/04/2018 – ABBVIE INC – SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS, WITH NO NEW SAFETY SIGNALS DETECTED; 17/04/2018 – REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Ph; 22/03/2018 – Moody’s: Abbvie’s Rova-T Results Credit Negative; 24/04/2018 – Shire says willing to recommend Takeda’s $64 bln offer to shareholders; 17/04/2018 – CYCLACEL’S CYC065 CDK INHIBITOR SHOWS SYNERGY WITH VENETOCLAX; 09/04/2018 – KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor…; 09/05/2018 – Immuno-Oncology Treatment Imfinzi for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada

Since February 19, 2018, it had 0 buys, and 10 sales for $26.80 million activity. 83,574 shares were sold by ALBAN CARLOS, worth $9.57 million on Wednesday, February 28. $1.75 million worth of stock was sold by RICHMOND TIMOTHY J. on Friday, June 15. Schumacher Laura J sold $2.95M worth of stock. 2,643 AbbVie Inc. (NYSE:ABBV) shares with value of $311,684 were sold by SEVERINO MICHAEL. $8.31 million worth of AbbVie Inc. (NYSE:ABBV) was sold by CHASE WILLIAM J on Wednesday, February 28. On Wednesday, February 28 the insider GONZALEZ RICHARD A sold $976,084. 992 shares valued at $119,351 were sold by Michael Robert A. on Monday, February 19.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It worsened, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. New York-based Canandaigua Bancorporation And Tru has invested 0.43% in AbbVie Inc. (NYSE:ABBV). Stearns Financial Service reported 15,481 shares. Bb&T stated it has 1.1% of its portfolio in AbbVie Inc. (NYSE:ABBV). Teachers Retirement Sys Of The State Of Kentucky reported 0.53% in AbbVie Inc. (NYSE:ABBV). Osterweis Capital Management Inc accumulated 3,670 shares. 22,319 are owned by Hyman Charles D. First Advsrs Limited Partnership holds 995,670 shares. 4,708 are owned by Sand Hill Advisors Limited Liability. Fort Point Cap Prtn Limited stated it has 116,284 shares or 2.95% of all its holdings. 6,000 were accumulated by Sather Group Incorporated. Rock Springs LP holds 600,000 shares or 2.42% of its portfolio. State Of Tennessee Treasury Department holds 0.55% or 1.14 million shares in its portfolio. Hollencrest Management owns 3,358 shares for 0.04% of their portfolio. Benedict Advsrs owns 2,394 shares. Texas-based Cypress Asset Mgmt Tx has invested 0.35% in AbbVie Inc. (NYSE:ABBV).

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc had 97 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, October 23 by UBS. The stock has “Buy” rating by Jefferies on Friday, September 15. The rating was downgraded by Goldman Sachs on Monday, March 7 to “Buy”. The firm has “Neutral” rating given on Monday, October 31 by Credit Suisse. Barclays Capital maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, October 13. Barclays Capital has “Equal-Weight” rating and $9 target. The company was maintained on Monday, February 26 by Jefferies. The firm has “Buy” rating given on Thursday, September 28 by Piper Jaffray. The rating was maintained by BMO Capital Markets on Sunday, July 30 with “Hold”. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, June 11 by Argus Research. The firm has “Buy” rating given on Tuesday, February 23 by Citigroup.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “Recent Stock Purchase June 2018” on June 23, 2018, also Seekingalpha.com with their article: “AbbVie: Growth And Dividend In One Package” published on June 15, 2018, Seekingalpha.com published: “More Thoughts On AbbVie’s Rova-T Implosion” on June 06, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Streetinsider.com and their article: “Put Buying Activity in AbbVie (ABBV) Highlights Bearish Options Bias -Susquehanna” published on June 22, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More” with publication date: June 03, 2018.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 EPS, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98B for 11.86 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

The stock increased 1.55% or $0.55 during the last trading session, reaching $35.95. About 16,015 shares traded or 64.24% up from the average. BSB Bancorp, Inc. (BLMT) has risen 15.64% since June 23, 2017 and is uptrending. It has outperformed by 3.07% the S&P500. Some Historical BLMT News: 19/04/2018 – BSB Bancorp 1Q EPS 64c; 19/04/2018 DJ BSB Bancorp Inc, Inst Holders, 1Q 2018 (BLMT)

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.